Epigenetic effects of the natural flavonolignan silibinin on colon adenocarcinoma cells and their derived metastatic cells

Kauntz,Henriette; Bousserouel,Souad; Gossé,Francine; Raul,Francis

doi:10.3892/ol.2013.1190

Epigenetic effects of the natural flavonolignan silibinin on colon adenocarcinoma cells and their derived metastatic cells

Authors:
- Henriette Kauntz
- Souad Bousserouel
- Francine Gossé
- Francis Raul
View Affiliations

Affiliations: Department of Nutritional Cancer Prevention, University of Strasbourg, Unit EA 4438, Faculty of Medicine, F-67000 Strasbourg, France, IRCAD-EITS, F-67000 Strasbourg, France
Published online on: February 12, 2013 https://doi.org/10.3892/ol.2013.1190
Pages: 1273-1277

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epigenetic modifications are important in tumorigenesis. The most frequent epigenetic phenomena in cancer are histone deacetylation and DNA hypermethylation, which lead to gene silencing, particularly of tumor suppressor genes. However, monotherapies with histone deacetylase (HDAC) or DNA methyltransferase (DNMT) inhibitors lack efficacy, hence there is a need to enhance their anticancer action in a safe and effective combination therapy. The present study investigated the epigenetic effects of the natural flavonolignan silibinin in a model of colon cancer progression, the primary adenocarcinoma cells SW480 and their derived metastatic cells SW620. Silibinin did not change the activity of HDACs, but it was able to significantly inhibit DNMT activity in both SW480 and SW620 cells. The clinically used HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA), and the broad spectrum HDAC inhibitor, trichostatin A (TSA), combined with silibinin demonstrated synergistic effects on cell death induction, may be related to its DNMT inhibition properties. The present data suggest that treatments combining silibinin and HDAC inhibitors may represent a promising approach, given the non-toxic nature of silibinin and the fact that HDAC inhibitors selectively target cancer cells.

View Figures

View References

1	Lu Q, Qiu X, Hu N, Wen H, Su Y and Richardson BC: Epigenetics, disease, and therapeutic interventions. Ageing Res Rev. 5:449–467. 2006. View Article : Google Scholar : PubMed/NCBI
2	Song SH, Han SW and Bang YJ: Epigenetic-based therapies in cancer: progress to date. Drugs. 71:2391–2403. 2011. View Article : Google Scholar : PubMed/NCBI
3	Carew JS, Giles FJ and Nawrocki ST: Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 269:7–17. 2008. View Article : Google Scholar : PubMed/NCBI
4	Mariadason JM: HDACs and HDAC inhibitors in colon cancer. Epigenetics. 3:28–37. 2008. View Article : Google Scholar : PubMed/NCBI
5	Ashktorab H, Belgrave K, Hosseinkhah F, Brim H, Nouraie M, Takkikto M, Hewitt S, Lee EL, Dashwood RH and Smoot D: Global histone H4 acetylation and HDAC2 expression in colon adenoma and carcinoma. Dig Dis Sci. 54:2109–2117. 2009. View Article : Google Scholar : PubMed/NCBI
6	Emanuele S, Lauricella M and Tesoriere G: Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review). Int J Oncol. 33:637–646. 2008.PubMed/NCBI
7	Wagner JM, Hackanson B, Lübbert M and Jung M: Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics. 1:117–136. 2010. View Article : Google Scholar : PubMed/NCBI
8	Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 3:415–428. 2002.PubMed/NCBI
9	Migliore L, Migheli F, Spisni R and Coppedè F: Genetics, cytogenetics, and epigenetics of colorectal cancer. J Biomed Biotechnol. 2011:7923622011. View Article : Google Scholar : PubMed/NCBI
10	Rius M and Lyko F: Epigenetic cancer therapy: rationales, targets and drugs. Oncogene. 31:4257–4265. 2012. View Article : Google Scholar : PubMed/NCBI
11	Cameron EE, Bachman KE, Myöhänen S, Herman JG and Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 21:103–107. 1999. View Article : Google Scholar : PubMed/NCBI
12	Thakur VS, Gupta K and Gupta S: Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases. Carcinogenesis. 33:377–384. 2012. View Article : Google Scholar : PubMed/NCBI
13	Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, Welsh W and Yang CS: Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 63:7563–7570. 2003.PubMed/NCBI
14	Fini L, Selgrad M, Fogliano V, Graziani G, Romano M, Hotchkiss E, Daoud YA, De Vol EB, Boland CR and Ricciardiello L: Annurca apple polyphenols have potent demethylating activity and can reactivate silenced tumor suppressor genes in colorectal cancer cells. J Nutr. 137:2622–2628. 2007.
15	Fang MZ, Chen D, Sun Y, Jin Z, Christman JK and Yang CS: Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy. Clin Cancer Res. 11:7033–7041. 2005. View Article : Google Scholar : PubMed/NCBI
16	Shu L, Khor TO, Lee JH, Boyanapalli SSS, Huang Y, Wu TY, Saw CL, Cheung KL and Kong AN: Epigenetic CpG demethylation of the promoter and reactivation of the expression of Neurog1 by curcumin in prostate LNCaP cells. AAPS J. 13:606–614. 2011. View Article : Google Scholar : PubMed/NCBI
17	Yan G, Graham K and Lanza-Jacoby S: Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells. Mol Carcinog. Jan 30–2012.(Epub ahead of print).
18	Lah JJ, Cui W and Hu KQ: Effects and mechanisms of silibinin on human hepatoma cell lines. World J Gastroenterol. 13:5299–5305. 2007. View Article : Google Scholar : PubMed/NCBI
19	Cui W, Gu F and Hu KQ: Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice. World J Gastroenterol. 15:1943–1950. 2009. View Article : Google Scholar : PubMed/NCBI
20	Mateen S, Raina K, Jain A, Agarwal C, Chan D and Agarwal R: Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells. Epigenetics. 7:1161–1172. 2012. View Article : Google Scholar : PubMed/NCBI
21	Kauntz H, Bousserouel S, Gossé F and Raul F: Silibinin triggers apoptotic signaling pathways and autophagic survival response in human colon adenocarcinoma cells and their derived meta-static cells. Apoptosis. 16:1042–1053. 2011. View Article : Google Scholar
22	Kauntz H, Bousserouel S, Gossé F, Marescaux J and Raul F: Silibinin, a natural flavonoid, modulates the early expression of chemoprevention biomarkers in a preclinical model of colon carcinogenesis. Int J Oncol. 41:849–854. 2012.PubMed/NCBI